- Home
- ZTO vs RPRX Comparison
ZTO vs RPRX Comparison
Compare ZTO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTO | RPRX |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 16.4B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZTO | RPRX |
|---|---|---|
| Price | $21.18 | $38.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $21.90 | ★ $45.75 |
| AVG Volume (30 Days) | 1.6M | ★ 4.3M |
| Earning Date | 11-19-2025 | 02-10-2026 |
| Dividend Yield | ★ 2.82% | 2.28% |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.16 | ★ 1.75 |
| Revenue | ★ $6,673,175,085.00 | $2,349,844,000.00 |
| Revenue This Year | $12.15 | $37.13 |
| Revenue Next Year | $11.36 | $1.48 |
| P/E Ratio | ★ $18.34 | $22.04 |
| Revenue Growth | ★ 13.17 | 3.70 |
| 52 Week Low | $16.34 | $24.05 |
| 52 Week High | $22.01 | $41.24 |
Technical Indicators
Market Signals| Indicator | ZTO | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 49.97 |
| Support Level | $20.73 | $38.20 |
| Resistance Level | $21.66 | $38.81 |
| Average True Range (ATR) | 0.35 | 0.74 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 50.89 | 37.67 |
Price Performance
Historical ComparisonAbout ZTO ZTO Express (Cayman) Inc. each representing one ordinary share.
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 19.4% in 2024. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 78% voting rights as of March 31, 2025. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 8.9% interest.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.